On Friday, Feb. 28, 2025, Cathie Wooden’s Ark Make investments made some notable trades. Essentially the most outstanding amongst these had been the purchases of Archer Aviation Inc ACHR, Recursion Prescription drugs Inc RXRX, Tempus AI Inc TEM, and Iridium Communications Inc IRDM.
Alternatively, Ark Make investments determined to dump shares of Twist Bioscience Corp TWST, Adyen NV ADYEY, Accolade Inc ACCD, and Precise Sciences Corp EXAS.
The ACHR Commerce
Ark Make investments bought a big variety of shares in Archer Aviation Inc throughout three of its ETFs. The ARK Innovation ETF ARKK purchased 360,583 shares, the ARK Autonomous Expertise & Robotics ETF ARKQ acquired 54,699 shares, and the ARK Area Exploration & Innovation ETF ARKX added 17,322 shares.
Based mostly on the closing worth of $8.88 on Friday, the overall worth of those trades is roughly $3.8 million.
The RXRX and TEM Trades
Ark Make investments additionally confirmed a powerful curiosity in Recursion Prescription drugs Inc and Tempus AI Inc. Ark Make investments beforehand bought a considerable variety of shares in Tempus AI regardless of the corporate’s inventory falling after reporting blended fourth-quarter outcomes.
Ark Make investments’s ARK Genomic Revolution ETF ARKG purchased 268,467 shares of Recursion Prescription drugs and 32,467 shares of Tempus AI.
The ARK Innovation ETF acquired 384,956 shares of Recursion Prescription drugs and 49,250 shares of Tempus AI.
Given the closing costs of $56.18 for Tempus AI and $7.51 for Recursion Prescription drugs, the overall worth of those trades is $36.7 million and $0.61 million, respectively.
The IRDM, TWST, ADYEY, ACCD, and EXAS Trades
Ark Make investments’s ARK Innovation ETF purchased 73,659 shares of Iridium Communications Inc, whereas promoting 65,290 shares of Twist Bioscience Corp.
The ARK Subsequent Era Web ETF offered a small variety of shares (52) of Adyen NV.
The ARK Genomic Revolution ETF offered 80,270 shares of Precise Sciences Corp and a minor amount (232) of Accolade Inc shares.
Learn Subsequent:
Disclaimer: This content material was partially produced with the assistance of AI instruments and was reviewed and printed by Benzinga editors.
Picture by way of Ark Make investments
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
